Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Notes:
By gender
Available studies, median, average
Countries with data available for the gender: Austria, Belgium, Cyprus, Czech Republic, Finland, Greece, Hungary, Italy, Malta, The Netherlands, Poland, Portugal, Slovenia, Slovakia, Turkey, United Kingdom
Number of samples: 410 (205 males; 205 females)
Total sample size: 348406
294480 (males); 53926 (females).
By age
Available studies, median and average
Countries with data available for the age: Austria, Belgium, Cyprus, Czezh Republic, Finland, Greece, Hungary, Malta, The Netherlands, Poland, Portugal, Slovenia, Slovakia, Turkey, United Kingdom
Number of samples: 343 (120, <25); (115, 25-34); (108, >34).
Total sample size: 36625
11570 (<25); 15416 (25-34); 9639 (>34)
By years of injection
Available studies, average and median
Countries with data available for years of injection: Austria, Belgium, Cyprus, Czech Republic, Greece, Poland, Portugal, Slovenia, Turkey, United Kingdom
Number of samples: 128 (59, <2 years); (69, >2 years)
Total sample size: 29962
8378 (<2 years); 21584 (>2 years)
By opioids/non-opioids use
Available studies, median and average
Countries with data available for primary drug: Austria, Belgium, Cyprus, Czech Republic, Greece, Malta, Poland, Portugal, Slovenia, Turkey
Number of samples: 96 (52 opiates; 44 non-opiates)
Total sample size: 7772
1363 (non-opiates); 6409 (opiates)
See also 'General notes for interpreting data' on the Explanatory notes and help page.
Sources:
Reitox national focal points.